• 1
    Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; Oct 19; (4): CD003961.
  • 2
    2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
  • 3
    Kershner RP, Fitzsimmons WE. Relationship of Fk506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920926.
  • 4
    Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 15761581.
  • 5
    Langton AK, Griffiths CE, Sherratt MJ, Watson RE. Cross-linking of structural proteins in ageing skin: An in situ assay for the detection of amine oxidase activity. Biogerontology 2012. Aug 26. [Epub ahead of print].
  • 6
    Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 27572763.
  • 7
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 18811884.
  • 8
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23: 12961310.
  • 9
    Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22e33.
  • 10
    Morrissey PE, Reinert S, Yango A, Gautam A, Monaco A, Gohh R. Factors contributing to acute rejection in renal transplantation: The role of noncompliance. Transplant Proc 2005; 37: 20442047.
  • 11
    Michelon T, Dominguez V, Losekan A, et al. Kidney graft failure due to noncompliance. Transplant Proc 1999; 31: 30313032.
  • 12
    Alloway RR, Mulgaonkar S, Bowers VD, al. e. A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo kidney transplant patients. Am J Transplant 2009; 9(Suppl 2): 414.
  • 13
    Alloway R, Mulgaonkar S, Ueda K, Cohen D, B. K. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs. Prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011; 11(Suppl 2): 355.
  • 14
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Clin Transplant 1998; 65: 515523.
  • 15
    Paris M, Rouleau M, Puceat M, Aberdam D. Regulation of skin aging and heart development by TAp63. Cell death and differentiation. 2012; 19: 186193.
  • 16
    Feldman HI, Hackett M, Bilker W, Strom BL. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents. Pharmacoepidemiol Drug Saf 1999; 8: 114.
  • 17
    Germani G, Lazzaro S, Gnoato F, et al. Nonadherent behaviors after solid organ transplantation. Transplant Proc 2011; 43: 318323.
  • 18
    Chisholm MA. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002; 62: 567575.
  • 19
    Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: A literature review. General Hospital Psychiatr 2000; 22: 412424.
  • 20
    Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388399.
  • 21
    Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237243.
  • 22
    Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410418.